India, Feb. 10 -- How does the revised implementation of Schedule M align India's pharmaceutical sector with global GMP standards?

Schedule M has been revised to align Indian pharmaceutical manufacturing with global Good Manufacturing Practices (GMP), bringing India closer to international regulatory expectations, and making our pharmaceutical products globally more competitive. The objective is to ensure consistent quality, safety, and efficacy, thereby strengthening India's reputation as a trusted supplier of medicines.

MSMEs often struggle with regulatory compliance. You had announced an extension for the compliance deadline to December 2025. What prompted this decision?

MSMEs play a crucial role in the pharmaceutical ecosystem, but...